Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 3
1966 5
1967 5
1968 7
1969 9
1970 5
1971 8
1972 9
1973 8
1974 15
1975 9
1976 9
1977 17
1978 8
1979 10
1980 12
1981 7
1982 10
1983 8
1984 11
1985 14
1986 9
1987 8
1988 16
1989 9
1990 22
1991 19
1992 15
1993 19
1994 11
1995 10
1996 16
1997 16
1998 18
1999 10
2000 16
2001 21
2002 31
2003 38
2004 24
2005 25
2006 23
2007 33
2008 23
2009 37
2010 40
2011 48
2012 68
2013 81
2014 86
2015 93
2016 96
2017 110
2018 99
2019 96
2020 91
2021 90
2022 101
2023 81
2024 31

Text availability

Article attribute

Article type

Publication date

Search Results

1,672 results

Results by year

Filters applied: . Clear all
Page 1
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2023 May;98(5):801-821. doi: 10.1002/ajh.26857. Epub 2023 Feb 6. Am J Hematol. 2023. PMID: 36680511 Free article. Review.
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticu …
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal …
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis.
Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J. Mesa RA, et al. J Clin Oncol. 2017 Dec 1;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418. Epub 2017 Sep 20. J Clin Oncol. 2017. PMID: 28930494 Free PMC article. Clinical Trial.
Patients and Methods Patients (N = 432) with high risk or intermediate-2 risk or symptomatic intermediate-1 risk myelofibrosis were randomly assigned to receive 24 weeks of treatment with momelotinib 200 mg once daily or ruxolitinib 20 mg twice a day (or per label), after …
Patients and Methods Patients (N = 432) with high risk or intermediate-2 risk or symptomatic intermediate-1 risk myelofibrosis were rando …
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Verstovsek S, et al. Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0. Lancet. 2023. PMID: 36709073 Clinical Trial.
Eligible patients were 18 years or older with a confirmed diagnosis of primary myelofibrosis or post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis. ...MOMENTUM is registered with ClinicalTrials.gov, number NCT04173494, and is active but not rec …
Eligible patients were 18 years or older with a confirmed diagnosis of primary myelofibrosis or post-polycythaemia vera or pos …
Momelotinib for the treatment of myelofibrosis with anemia.
Tremblay D, Mesa R. Tremblay D, et al. Future Oncol. 2022 Jun;18(20):2559-2571. doi: 10.2217/fon-2022-0276. Epub 2022 May 23. Future Oncol. 2022. PMID: 35603634 Free article. Review.
Momelotinib is a JAK1/JAK2 inhibitor that also antagonizes ACVR1, leading to downregulation of hepcidin expression and increased availability of iron for erythropoiesis. In clinical testing, momelotinib has demonstrated a unique ability to improve hemoglobin and reduce tra …
Momelotinib is a JAK1/JAK2 inhibitor that also antagonizes ACVR1, leading to downregulation of hepcidin expression and increased availabilit …
Management of myelofibrosis after ruxolitinib failure.
Harrison CN, Schaap N, Mesa RA. Harrison CN, et al. Ann Hematol. 2020 Jun;99(6):1177-1191. doi: 10.1007/s00277-020-04002-9. Epub 2020 Mar 20. Ann Hematol. 2020. PMID: 32198525 Free PMC article. Review.
Fedratinib and two other JAK2 inhibitors in later stages of clinical development, pacritinib and momelotinib, have been shown to induce clinical responses and improve symptoms in patients previously treated with ruxolitinib. ...Reviewed here are strategies to amelio …
Fedratinib and two other JAK2 inhibitors in later stages of clinical development, pacritinib and momelotinib, have been shown to indu …
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. Verstovsek S, et al. N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557. N Engl J Med. 2012. PMID: 22375971 Free PMC article. Clinical Trial.
BACKGROUND: Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis. METHODS: In this double-blind trial, we randomly assigned patients with intermediate-2 or high-risk myelofibrosis to twice-daily oral …
BACKGROUND: Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis. METHODS: …
Momelotinib: an emerging treatment for myelofibrosis patients with anemia.
Chifotides HT, Bose P, Verstovsek S. Chifotides HT, et al. J Hematol Oncol. 2022 Jan 19;15(1):7. doi: 10.1186/s13045-021-01157-4. J Hematol Oncol. 2022. PMID: 35045875 Free PMC article. Review.
The suite of marked anemia benefits that momelotinib has consistently conferred on myelofibrosis (MF) patients stem from its unique inhibitory activity on the BMP6/ACVR1/SMAD and IL-6/JAK/STAT3 pathways, resulting in decreased hepcidin (master iron regulator) expression, higher s …
The suite of marked anemia benefits that momelotinib has consistently conferred on myelofibrosis (MF) patients stem from its unique inhibito …
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S. Mascarenhas J, et al. JAMA Oncol. 2018 May 1;4(5):652-659. doi: 10.1001/jamaoncol.2017.5818. JAMA Oncol. 2018. PMID: 29522138 Free PMC article. Clinical Trial.
Crossover from BAT was allowed after week 24 or for progression of splenomegaly. INTERVENTIONS: Patients were randomized 1:1:1 to pacritinib 400 mg once daily, pacritinib 200 mg twice daily, or BAT. ...The intention-to-treat efficacy population included 75 patients rand …
Crossover from BAT was allowed after week 24 or for progression of splenomegaly. INTERVENTIONS: Patients were randomized 1:1:1 to pac …
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
Verstovsek S, Mesa R, Gupta V, Lavie D, Dubruille V, Cambier N, Platzbecker U, Hus M, Xicoy B, Oh ST, Kiladjian JJ, Vannucchi AM, Gerds A, Egyed M, Mayer J, Sacha T, Kawashima J, Morris M, Huang M, Harrison C. Verstovsek S, et al. Blood Adv. 2023 Jul 25;7(14):3582-3591. doi: 10.1182/bloodadvances.2022009311. Blood Adv. 2023. PMID: 37042865 Free PMC article.
The most common reason for momelotinib discontinuation was thrombocytopenia (4% discontinuation rate). The incidence of AEs of clinical importance (eg, infections, malignant transformation, peripheral neuropathy, and hemorrhage) did not increase over time. This analysis of …
The most common reason for momelotinib discontinuation was thrombocytopenia (4% discontinuation rate). The incidence of AEs of clinical …
Primary myelofibrosis and its targeted therapy.
Shantzer L, Berger K, Pu JJ. Shantzer L, et al. Ann Hematol. 2017 Apr;96(4):531-535. doi: 10.1007/s00277-016-2785-9. Epub 2016 Aug 19. Ann Hematol. 2017. PMID: 27539616 Review.
Primary myelofibrosis is a unique entity among BCR-ABL-negative myeloproliferative diseases, manifesting as bone marrow fibrosis and pancytopenia. ...This study reviews current concepts and questions regarding the pathogenesis of primary myelofibrosis …
Primary myelofibrosis is a unique entity among BCR-ABL-negative myeloproliferative diseases, manifesting as bone marrow fibros …
1,672 results